Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders

Obesity Reviews

Volumn 12, Issue 10, 2011, Pages 813-828

  Paschetta, E ^a   Hvalryg, M ^b   Musso, G ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b Helgelandssykehu set ^*  (Norway)

^c GRADENIGO HOSPITAL   (Italy)

Author keywords

GIP; Incretin; K cell; Obesity

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INCRETIN; INSULIN; LIPID; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ARTICLE; BYPASS SURGERY; CALORIC INTAKE; CELL METABOLISM; CELL PROLIFERATION; DIABETES MELLITUS; GLUCOSE METABOLISM; HORMONAL REGULATION; HORMONE RELEASE; HORMONE SENSITIVITY; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; INTESTINE CELL; KILLER CELL; LIPID METABOLISM; LIPID STORAGE; LIVER; METABOLIC REGULATION; MORBID OBESITY; MUSCLE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; SMALL INTESTINE;

BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; FATTY LIVER; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; OBESITY;

EID: 80053132665     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2011.00897.x     Document Type: Article

References (137)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
2. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
3. Ranganath L. The entero-insular axis: implications for human metabolism. Clin Chem Lab Med 2008; 46: 43-56.
4. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and non diabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206.
5. Fushiki T, Kojima A, Imoto T, Inoue K, Sugimoto E. An extract of Gymnema sylvestre leaves and purified gymnemic acid inhibits glucosestimulated gastric inhibitory peptide secretion in rats. J Nutr 1992; 122: 2367-2373.
6. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128: 117-124.
7. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 2008; 8: 532-539.
8. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009; 52: 289-298.
9. Cheung AT, Dayanandan B, Lewis JT, Korbutt GS, Rajotte RV, Bryer-Ash M. Glucose-dependent insulin release from genetically engineered K cells. Science 2000; 290: 1959-1962.
10. Kieffer TJ, Buchan AM, Barker H, Brown JC, Pederson RA. Release of gastric inhibitory polypeptide from cultured canine endocrine cells. Am J Physiol 1994; 267(Pt 1): E489-E496.
11. Ramshur EB, Rull TR, Wice BM. Novel insulin/GIP Co-producing cell lines provide unexpected insights into gut K-cell function in vivo. J Cell Physiol 2002; 192: 339-350.
12. Nielsen LB, Ploug KB, Swift P, Orskov C, Jansen-Olesen I, Chiarelli F. Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. Eur J Endocrinol 2007; 156: 663-671.
13. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucoseinduced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007; 92: 4165-4171.
14. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43.
15. Chandrashekar J, Hoon MA, Ryba NJ, Zuker CS. The receptors and cells for mammalian taste. Nature 2006; 444: 288-294.
16. Dyer J, Salmon KS, Zibrik L, Shirazi-Beechey SP. Expression of sweet taste receptors of the T1R family in the intestinal tract and enteroendocrine cells. Biochem Soc Trans 2005; 33: 302-305.
17. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A 2007; 104: 15069-15074.
18. Fujita Y, Wideman RD, Speck M, Asadi A, King DS, Webber TD. Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. Am J Physiol Endocrinol Metab 2009; 296: E473-E479.
19. Ma J, Bellon M, Wishart JM, Young R, Blackshaw LA, Jones KL. Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009; 296: G735-G739.
20. Rijkelijkhuizen JM, McQuarrie K, Girman CJ, Stein PP, Mari A, Holst JJ etal. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. Metabolism 2010; 59: 502-511.
21. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-126.
22. Wachters-Hagedoorn RE, Priebe MG, Heimweg JAJ, Heiner AM, Englyst KN, Holst JJ etal. The rate of intestinal glucose absorption is correlated with plasma glucose-dependent insulinotropic polypeptide concentration in healthy men. J Nutr 2006; 136: 1511-1516.
23. Ellrichmann M, Kapelle M, Ritter PR, Holst JJ, Herzig KH, Schmidt WE. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab 2008; 93: 3995-3998.
24. Enç FY, Ones T, Akin HL, Dede F, Turoglu HT, Ulfer G. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009; 296: G482-G489.
25. Kwasowski P, Flatt PR, Bailey CJ, Marks V. Effects of fatty acid chain length and saturation on gas tric inhibitory polypeptide release in obese hyperglycaemic (ob/ob) mice. Biosci Rep 1985; 5: 701-705.
26. Thomsen C, Rasmussen O, Lousen T, Holst JJ, Fenselau S, Schrezenmeir J. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 1999; 69: 1135-1143.
27. Shimotoyodome A, Suzuki J, Fukuota D, Tokimitsu I, Hase T. RS4-type resistant starch prevents high-fat diet-induced obesity via increased hepatic fatty acid oxidation and decreased postprandial GIP in C57B/6J. Am J Physiol Endocrinol Metab 2010; 298: E652-E662.
28. Iakoubov R, Izzo A, Yeung A, Whiteside CI, Brubaker PL. Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology 2007; 148: 1089-1098.
29. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM. The orphan G protein coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003; 278: 11303-11311.
30. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005; 11: 90-94.
31. Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI, Kuwahara A. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol 2008; 59: 251-262.
32. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagonlike peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009; 58: 1058-1066.
33. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A. A role for intestinal endocrine cell expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 2008; 149: 2038-2047.
34. Flock G, Holland D, Seino Y, Drucker DJ. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 2011; 152: 374-383.
35. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008; 57: 2280-2287.
36. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008; 57: 2432-2437.
37. Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 2009; 201: 219-230.
38. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, Brubaker PL. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology 2009; 150: 580-591.
39. Alquier T, Poitout V. GPR40: good cop, bad cop? Diabetes 2008; 58: 1035-1036.
40. Gniuli D, Dalla Libera L, Caristo ME, Calvani R, Castagneto M, Mingrone G. High saturated-fat diet induces apoptosis in rat enterocytes and blunts GIP and insulin-secretive responses to oral glucose load. Int J Obes 2008; 32: 871-874.
41. Thomas FB, Sinar D, Mazzaferri EL, Cataland S, Mekhjian HS, Celdwell JH. Selective release of gastric inhibitory polypeptide by intraduodenal amino acid perfusion in man. Gastroenterology 1978; 74: 1261-1265.
42. Cordier-Bussat M, Bernard C, Levenez F, Klages N, Laser-Ritz B, Philippe J. Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. Diabetes 1998; 47: 1038-1045.
43. Gunnarsson PT, Winzell MS, Deacon CF, Larsen MO, Jelic K, Carr RD etal. Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology 2006; 147: 3173-3180.
44. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 2005; 108: 277-292.
45. Lu WJ, Yang Q, Sun W, Woods SC, D'Alessio D, Tso P. Using the lymph fistula rat model to study the potentiation of GIP secretion by the ingestion of fat and glucose. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1130-G1138.
46. Yang L, Li X, Ji Y, Kohan AB, Wang DQH, Howles PN, Hui DJ etal. Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1003-G1011.
47. Gupta D, Peshavaria M, Monga N, Jetton TL, Leahy JL. Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes. Diabetes 2010; 59: 1445-1450.
48. Leahy JL. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis. Curr Diab Rep 2009; 9: 215-220.
49. Shimotoyodome A, Fukuoka D, Suzuki J, Fujii Y, Mizuno T, Meguro S etal. Coingestion of acylglycerols differentially affects glucose-induced insulin secretion via glucose-dependent insulinotropic polypeptide in C57BL/6J mice. Endocrinology 2009; 150: 2118-2126.
50. Dekker MJ, Graham TE, Ooi TC, Robinson LE. Exercise prior to fat ingestion lowers fasting and postprandial VLDL and decreases adipose tissue IL-6 and GIP receptor mRNA in hypertriacylglycerolemic men. J Nutr Biochem 2010; 21: 983-990.
51. Villareal DT, Robertson H, Bell GI, Patterson BW, Tran H, Wice B etal. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010; 59: 479-485.
52. Musso G, Gambino R, Pacini G, De Michieli F, Cassader M. Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. Am J Clin Nutr 2009; 89: 1-10.
53. Garcia-Martinez JM, Chocarro-Calvo A, Moya CM, Garcia-Jimenez C. WNT/beta-catenin increases the production of incretins by entero-endocrine cells. Diabetologia 2009; 52: 1913-1924.
54. Gustafson B, Smith U. Wnt signaling is both an inducer and effector of glucagon-like peptide-1. Diabetologia 2008; 51: 768-770.
55. Greenberg GR, Pokol-Daniel S. Neural modulation of glucosedependent insulinotropic peptide (GIP) and insulin secretion in conscious dogs. Pancreas 1994; 9: 531-535.
56. Ahren B, Holst JJ. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 2001; 50: 1030-1038.
57. Flaten O, Sand T, Myren J. Beta-adrenergic stimulation and blockade of the release of gastric inhibitory polypeptide and insulin in man. Scand J Gastroenterol 1982; 17: 283-288.
58. Salera M, Ebert R, Giacomoni P, Pironi L, Venturi S, Corinaldesi R. Adrenergic modulation of gastric inhibitory polypeptide secretion in man. Dig Dis Sci 1982; 27: 794-800.
59. Kieffer TJ, Buchan AM, Barker H, Brown JC, Pederson RA. Release of gastric inhibitory polypeptide from cultured canine endocrine cells. Am J Physiol 1994; 267: E489-E496.
60. Damholt AB, Buchan AM, Kofod H. Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose. Endocrinology 1998; 139: 2085-2091.
61. Yavropoulou MP, Kotsa K, Kesisoglou I, Anastasiou O, Yovos JG. Intracerebroventricular infusion of neuropeptide Y increases glucose dependent-insulinotropic peptide secretion in the fasting conscious dog. Peptides 2008; 29: 2281-2285.
62. Yavropoulou MP, Kotsa K, Anastasiou OE, O'Dorisio TM, Pappas TN, Yovos JG. Intracerebroventricular infusion of bombesin modulates GIP secretion in conscious dogs. Neuropharmacology 2010; 58: 226-232.
63. Yavropoulou MP, Kotsa K, Kesisoglou I, Gotzamani-Psarakou A, Yovos JG. Effect of intracerebroventricular infusion of neurotensin in glucose-dependent insulinotropic peptide secretion in dogs. Peptides 2010; 31: 150-154.
64. Yavropoulou MP, Kotsa K, Anastasiou O, O'Dorisio TM, Pappas TN, Yovos JG. Effect of intracerebroventricular infusion of insulin on glucose-dependent insulinotropic peptide in dogs. Neurosci Lett 2009; 460: 148-151.
65. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861-2870.
66. Herrmann-Rinke C, Voge A, Hess M, Goke B. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol 1995; 147: 25-31.
67. Roberge JN, Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993; 133: 233-240.
68. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like Peptide-1 secretion. Endocrinology 1999; 140: 1687-1694.
69. Simpson AK, Ward PS, Wong KY, Collord GJ, Habib AM, Reimann F etal. Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia 2007; 50: 2181-2189.
70. Hansen L, Holst JJ. The effects of duodenal peptides on glucagonlike peptide-1 secretion from the ileum. A duodeno - ileal loop? Regul Pept 2002; 110: 39-45.
71. Brubaker PL. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 2010; 151: 1984-1989.
72. Wang Y, Montrose-Rafizadeh C, Adams L, Raygada M, Nadiv O, Egan JM. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Mol Cell Endocrinol 1996; 116: 81-87.
73. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signalling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 2002; 174: 233-246.
74. McIntosh CHS, Widenmaier S, Kim SJ. Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide; GIP). Vitam Horm 2009; 80: 409-471.
75. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE etal. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subject at normoglycaemia. Diabetologia 2003; 46: 798-801.
76. Getty-Kaushik L, Song DH, Boylan MO, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity (Silver Spring) 2006; 14: 1124-1131.
77. Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Unger RH. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest 1981; 68: 1106-1107.
78. Ebert R, Nauck M, Creutzfeldt W. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm Metab Res 1991; 23: 517-521.
79. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H etal. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.
80. Starich GH, Bar RS, Mazzaferri EL. GIP increases insulin receptor affinity and cellular sensitivity in adipocytes. Am J Physiol Endocrinol Metab 1985; 249: E603-E607.
81. Asmar M, Tangaa W, Madsbad S, Hare K, Astrup A, Flint A etal. On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Am J Physiol Endocrinol Metab 2010; 298: E614-E621.
82. Asmar M, Simonsen L, Madsbad S, Stallknecht B, Holst JJ, Bülow J. GIP may enhance fatty acid re-esterification in subcutaneous, abdominal adipose tissue in lean humans. Diabetes 2010; 59: 2160-2163.
83. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 2007; 282: 34139-34147.
84. Song DH, Getty-Kaushik L, Tseng E, Simon J, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through akt activation. Gastroenterology 2007; 133: 1796-1805.
85. Weaver RE, Donnelly D, Wabitsch M, Grant PJ, Balmforth AJ. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model. Int J Obes (Lond) 2008; 32: 1705-1711.
86. Rudovich N, Kaiser S, Engeli S, Osterhoff M, Gögebakan O, Bluher M etal. GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women. Regul Pept 2007; 142: 138-145.
87. Timper K, Grisouard J, Radimerski T, Dembinski K, Peterli R, Haring A etal. Glucose-dependent insulinotropic polypeptide (GIP) induces calcitonin gene-related peptide (CGRP)-I and procalcitonin (Pro-CT) production in human adipocytes. J Clin Endocrinol Metab 2011; 96: E297-E303.
88. Kreutter DK, Orena SJ, Torchia AJ, Contillo LG, Andrews GC, Stevenson RW. Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor. Am J Physiol 1993; 264: E606-E613.
89. Ahren B. Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man. Acta Endocrinol (Copenh) 1990; 123: 591-597.
90. Nyberg J, Anderson MF, Meister B, Alborn AM, Ström AK, Brederlau A etal. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 2005; 25: 1816-1825.
91. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S etal. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004; 110: 36-43.
92. Ranganath L, Daousi C, Cleator J, Pinkney J, Wilding JP. Effects of GLP-1 and GIP on energy expenditure and appetite in type 2 diabetes. Ann Clin Biochem (National Meeting) 2007; 44: T25.
93. Daousi C, Wilding JP, Aditya S, Durham BH, Cleator J, Pinkney JH etal. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol (Oxf) 2009; 71: 195-201.
94. Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M etal. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 2006; 20: 1644-1651.
95. Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B etal. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab 2007; 292: E543-E548.
96. Ballica R, Valentijn K, Khachatryan A, Guerder S, Kapadia S, Gundberg C etal. Targeted expression of calcitonin gene-related peptide to osteoblasts increases bone density in mice. J Bone Miner Res 1999; 14: 1067-1074.
97. Bollag RJ, Zhong Q, Phillips P, Min L, Zhong L, Cameron R etal. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000; 141: 1228-1235.
98. Bjarnson NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. Bone 2002; 30: 307-313.
99. Ding KH, Shi XM, Zhong Q, Kang B, Xie D, Bollaq WB etal. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res 2008; 23: 536-543.
100. Prabakaran D, Wang B, Feuerstein JD, Sinclair JA, Bijpuria P, Jepeal LI etal. Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells. Regul Pept 2010; 163: 74-80.
101. Huang X-F, Chen J-Z. Obesity, the PI3/Akt signal pathway and colon cancer. Obes Rev 2009; 10: 610-616.
102. Hursting SD, Nunez NP, Varticovski L, Vinson C. The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res 2007; 67: 2391-2393.
103. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
104. Theodorakis MJ, Carlson O, Muller DC, Egan JM. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 2004; 27: 1692-1698.
105. Zhou J, Livak MFA, Bernier M, Muller DC, Carlson OD, Elahi D etal. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab 2007; 293: E538-E547.
106. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K. Downregulation of GLP-1 and GIP receptor expression by hyperglycaemia - possible contribution to impaired incretin effects in diabetes. Diabetes 2007; 56: 1551-1558.
107. Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009; 58: 1342-1349.
108. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115-121.
109. Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE etal. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57: 678-687.
110. Sauber J, Grothe J, Behm M, Scherag A, Grallert H, Illig T etal. Association of variants in the glucose dependent insulinotropic peptide receptor gene (GIPR) with impaired glucose homeostasis in obese children and adolescents from Berlin. Eur J Endocrinol 2010; 163: 259-264.
111. Zhou H, Yamada Y, Tsukiyama K, Miyawaki K, Hosokawa M, Nagashima K etal. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun 2005; 335: 937-942.
112. Carr RD, Larsen MO, Jelic K, Lindgren O, Vikman J, Holst JJ etal. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 2010; 95: 872-878.
113. Vogel CIG, Scherag A, Brönner G, Nguyen TT, Wang HJ, Grallert H etal. Gastric inhibitory polypeptide receptor: association analyses for obesity of several polymorphisms in large study groups. BMC Med Genet 2009; 10: 19.
114. Gault VA, Irwin V, Green BD, McCluskey JT, Greer B, Bailey CJ etal. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 2005; 54: 2436-2446.
115. Irwin N, Gault VA, Green BD, Greer B, McCluskey JT, Harriott P etal. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. J Biol Chem 2004; 385: 845-852.
116. McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR. GIP receptor antagonism reverses obesity, insulin resistance and associated metabolic disturbances induced in mice by prolonged consumption of high fat diet. Am J Physiol Endocrinol Metab 2007; 293: E1746-E1755.
117. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Hernandez R, Marco J. Stimulatory effect of xenin-8 on insulin and glucagon secretion in the perfused rat pancreas. Regul Pept 2003; 115: 25-29.
118. Feurle GE. Xenin - a review. Peptides 1998; 19: 609-615.
119. Heuser M, Kleiman I, Popken O, Nustede R, Post S. Evidence for non-neurotensin receptor-mediated effects of xenin (1-25) - focus on intestinal microcirculation. Regul Pept 2002; 107: 23-27.
120. Althage MC, Ford EL, Wang S, Tso P, Polonsky KS, Wice BM. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem 2008; 283: 18365-18376.
121. Kim SJ, Nian C, McIntosh CH. Activation of lipoprotein lipase (LPL) by glucosedependent insulinotropic polypeptide (GIP) in adipocytes: a role for a protein kinase B (PKB), LKB1 and AMP-activated protein kinase (AMPK) cascade. J Biol Chem 2007; 282: 8557-8567.
122. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K etal. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004; 53: 1326-1335.
123. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y etal. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007; 117: 143-152.
124. Nagao K, Inoue N, Wang YM, Shirouchi B, Yanagita T. Dietary conjugated linoleic acid alleviates nonalcoholic fatty liver disease in Zucker (fa/fa) rats. J Nutr 2005; 135: 9-13.
125. Ide T. Interaction of fish oil and conjugated linoleic acid in affecting hepatic activity of lipogenic enzymes and gene expression in liver and adipose tissue. Diabetes 2005; 54: 412-423.
126. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006; 281: 12093-12101.
127. Tushuizen ME, Bunck MC, Pouwels PJ, Van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006; 26: 1015-1017.
128. Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists vs. DPP-4 inhibition in high fat fed mice. Diabetes 2008; 57: 190-198.
129. Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL. Hormonal changes after Roux-en-Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004; 70: 1-5.
130. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J etal. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240: 236-242.
131. Rao RS, Kini S. GIP and bariatric surgery. Obes Surg 2011; 21: 244-252.
132. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gnuili D, Mari A etal. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006; 55: 2025-2031.
133. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008; 51: 1781-1789.
134. Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A etal. Effect of weight loss by gastric bypass surgery vs. hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 2479-2485.
135. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V etal. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108-114.
136. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007; 3: 597-601.
137. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006; 290: 550-559.